ClinicalTrials.gg
RecruitingNCT07394712NAPOLEONUpdated Nov 4, 2026

Comprehensive Maintenance Program: a Health Haven for COPD in Lleida.The NAPOLEON Project.

An interventional study of Interdisciplinary intervention in COPD - Chronic Obstructive Pulmonary Disease, Pulmonary Rehabilitation and Randomised Controlled Trial, sponsored by Institut de Recerca Biomèdica de Lleida. Recruiting at 2 sites in Spain. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institut de Recerca Biomèdica de Lleida · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain — 42 open to participants now, 45 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Spain.

Planned enrollment
182nd of 238
86 · median 336
Started
2025
with 18 others
No phase
68 of 309
13 open now
Primary completion
2027-10
later than 32 of 44 live
Registered
293rd of 309
by date

Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, this one is the 182nd largest by planned enrollment of the 238 interventional ones that give a count, is one of 19 that started in 2025, is one of 68 with no phase, reaches primary completion later than 32 of the 44 other live ones, and was the 293rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, or all of them as a file.
02

Study summary

Introduction:

Pulmonary rehabilitation programs (PRPs) are known to reduce symptoms such as dyspnea and fatigue, while improving functional capacity and quality of life in individuals with chronic obstructive pulmonary disease (COPD). However, the benefits of an initial pulmonary rehabilitation program (PRP) tend to diminish rapidly over time, prompting the development of strategies to maintain these effects. Such strategies include supervised exercise programs, telephone follow-ups, and home-based exercise regimens. Nevertheless, the optimal maintenance strategy remains uncertain.

Objectives:

The primary objective is to evaluate the impact of a supervised, multidimensional maintenance PRP on symptoms and quality of life in individuals with COPD. Additionally, the study aims to compare exercise capacity, healthcare resource utilization, economic benefits, and participant perceptions between the intervention and control groups.

Methodology:

A 12-month randomized controlled trial (RCT) with two parallel groups will be conducted in adults with COPD who have completed an initial 8-week PRP. Participants will be randomly assigned in a 1:1 ratio to either the intervention or control group. The intervention group will undergo a maintenance PRP consisting of two weekly supervised exercise sessions and monthly educational sessions on COPD in a comprehensive health center over a 3-month period. The control group will receive standard clinical care recommendations regarding physical activity. Clinical evaluations will be conducted at four time points throughout the study: baseline (T0), 3 months (T1), 6 months (T2), and 12 months (T3). Full pulmonary function tests and anthropometric assessments will be performed at T0 and T3. Other variables, including symptom burden, quality of life, functional capacity, mental health, physical activity, sleep-wake pattern, and healthcare utilization, will be systematically collected at all four time points.

Read the detailed description

Justification Pulmonary rehabilitation programs (PRPs) are a cost-effective therapeutic strategy to reduce dyspnea, improve exercise tolerance, and enhance health-related quality of life in individuals with chronic obstructive pulmonary disease (COPD). Conventional PRPs typically last between 6 and 8 weeks and include physical training, education, and psychosocial support. However, multiple studies have shown that the benefits gained tend to diminish within 3 to 6 months after the initial program ends, especially when structured follow-up and maintenance strategies are not implemented.

In response to this issue, various post-PRP maintenance program modalities have been proposed, such as supervised or unsupervised home-based programs, periodic telephone follow-ups, or group exercise sessions. Despite promising results from some clinical trials, the evidence remains heterogeneous and limited, both in terms of clinical efficacy and feasibility within public health systems. International clinical practice guidelines have emphasized the urgent need to evaluate sustainable and economically viable strategies to maintain the benefits of PRPs, particularly in contexts where structured continuity of care is not guaranteed.

The present study involves the implementation of a supervised maintenance post-pulmonary rehabilitation program (PRP) in an outpatient setting, adequately equipped for the intervention and coordinated by a physiotherapist affiliated with a specialized clinical setting. This intervention will consist of a three-month interdisciplinary maintenance program with biweekly supervised physical exercise sessions, education on COPD and healthy lifestyle habits, and strategies for early detection of exacerbations. It is designed as a randomized controlled trial (RCT) with a 12-month follow-up and clinical evaluations at baseline (T0), 3 months (T1), 6 months (T2), and 12 months (T3).

Specific Objectives

  1. To compare general and COPD-specific health-related quality of life between intervention and control groups at T0, T1, T2, and T3 using the EuroQol-5 Dimensions questionnaire (EQ-5D) and the COPD Assessment Test (CAT).
  2. To assess the impact of the intervention on mental health by comparing anxiety and depression levels between groups at T0, T1, T2, and T3, measured with the Hospital Anxiety and Depression Scale (HADS).
  3. To compare functional and exercise capacity between groups at T0, T1, T2, and T3, based on spirometry values, the six-minute walk test (6MWT), and handgrip strength.
  4. To compare self-reported physical activity levels using the short version of the International Physical Activity Questionnaire (IPAQ) across time points.
  5. To evaluate the sleep-wake pattern and determine the intervention's effect on its modulation, through analysis of sleep-wake pattern and activity variables (total sleep time, sleep latency, wake after sleep onset, light and deep sleep stages) recorded by wearable devices throughout the follow-up.
  6. To compare healthcare utilization at T3, including non-hospitalized exacerbations, hospital admissions, and total hospitalization days between groups.
  7. To assess the cost-effectiveness of the intervention from the healthcare system perspective, considering direct healthcare-related costs and the clinical benefits achieved.

Study Design This study will be conducted as a 12-month randomized controlled trial (RCT) with four clinical assessment visits, involving two parallel groups of adults diagnosed with chronic obstructive pulmonary disease (COPD) who have completed an initial eight-week PRP. Clinical evaluations will take place at four time points: baseline (T0), 3 months (T1), 6 months (T2), and 12 months (T3). Comprehensive pulmonary function tests and anthropometric measurements will be performed at T0 and T3. Other variables (symptoms, quality of life, functional capacity, mental health, physical activity, sleep-wake pattern, and healthcare utilization) will be assessed at all four time points. Participants will be randomly assigned in a 1:1 ratio to either the intervention or control group. The intervention group will attend two weekly supervised exercise sessions and two monthly educational sessions at a public health-affiliated center for three months. The control group will receive general physical activity recommendations in line with standard clinical practice. Clinical assessments will be conducted at T0, T1, T2, and T3, covering respiratory symptoms, health-related quality of life, functional capacity, and healthcare service use.

No booster phase is planned beyond the three-month intervention, as one of the study's secondary objectives is to explore the duration of maintenance PRP effects post-intervention. This will help determine whether clinical, functional, and sleep-wake pattern benefits persist in the medium and long term without continued intervention.

The program includes six educational sessions (20 minutes each), delivered monthly over three months and structured into six key thematic areas:

  1. Knowledge about chronic obstructive pulmonary disease (COPD).
  2. How dyspnea affects us and how to control it.
  3. Importance of physical activity and exercise.
  4. Malnutrition and obesity in chronic obstructive pulmonary disease (COPD).
  5. Good sleep hygiene is important.
  6. Smoking and alcohol cessation.

Adverse Events: Any adverse events observed during the intervention that led to exercise discontinuation will be recorded in an Adverse Event Report Form by the session physiotherapist and reported to the trial's coordinating physiotherapist. As previously stated, if exacerbations are detected, the patient will be referred to the hospital's specialized chronic obstructive pulmonary disease (COPD) clinic. Moreover, as outlined in Table 2, Section 6 (Supervision and Safety), the protocol includes professional supervision during the intervention, individualized adaptation and ongoing monitoring, and supplemental oxygen therapy if necessary.

Randomization: Patients will be randomized 1:1 into two study groups using a sequence generated by an electronic system external to the research team. The randomization sequence will remain concealed from the investigators until an eligible patient has provided written informed consent. Investigators will have secure, password-protected access to the system 24/7.

Blinding: Role separation will allow for blinding of the outcome assessor and personnel involved in data analysis and interpretation of treatment allocation.

Clinical and Functional Variable Evaluation Timeline: Clinical assessments will occur at baseline (T0), 3 months (T1), 6 months (T2), and 12 months (T3). Full spirometry and anthropometric measurements will be conducted at T0 and T3. All other variables (symptoms, quality of life, functional capacity, mental health, physical activity, sleep-wake pattern, and healthcare use) will be assessed at each time point. These include clinical characteristics of chronic obstructive pulmonary disease (COPD) (total number of exacerbations and hospitalizations, and events during the previous year); respiratory symptoms using the Dyspnea-12 questionnaire; mental health via the Hospital Anxiety and Depression Scale (HADS); general quality of life through the EuroQol-5 Dimensions questionnaire (EQ-5D) and COPD-specific quality of life with the COPD Assessment Test (CAT); aerobic capacity via the six-minute walk test (6MWT); handgrip strength using dynamometry; and physical activity levels via the short form of the International Physical Activity Questionnaire (IPAQ). The sleep-wake pattern will be continuously monitored over the 12-month follow-up using wrist-worn devices in both groups to analyze key sleep variables. Adherence to the intervention will be assessed by calculating average session attendance at T3, as will healthcare resource use.

Cost-Effectiveness Analysis: Cost-effectiveness analysis will be conducted using the intention-to-treat principle. Costs during the 12-month study period will be evaluated for both groups. The analysis will adopt a healthcare system perspective, focusing exclusively on patient health outcomes and direct provider-borne costs. The time horizon is 12 months, and all costs will be reported in 2025 euros (€). The intervention's impact on quality of life will be estimated through quality-adjusted life years (QALYs), based on the Health Utilities Index (HUI) derived from EuroQol-5 Dimensions questionnaire (EQ-5D), using the formula: QALYs = 0.5 × baseline HUI + 0.5 × 12-month HUI.

To manage missing data, multiple imputation will be applied independently using the Multivariate Imputation by Chained Equations (MICE) method with predictive mean matching. Initially, the database will be stratified by treatment group to ensure group-specific imputations. The imputation process will include costs, Health Utilities Index (HUI), age, sex, and body mass index (BMI).

To illustrate uncertainty in cost-effectiveness outcomes, 5,000 nonparametric bootstrap replications of cost and effectiveness pairs will be simulated. Pooled cost-effectiveness estimates will be calculated using Rubin's rules and plotted on a cost-effectiveness plane.

Sample Size: Sample size was calculated based on the primary outcome, Dyspnea-12. A clinically relevant difference of 2.83 points at 12-month follow-up was considered. Assuming a common standard deviation of 5 points, a significance level of 0.05, 80% statistical power, and a 10% dropout rate, a total of 43 participants per group is estimated to be required to detect this difference.

03

Conditions studied

  • COPD - Chronic Obstructive Pulmonary Disease
  • Pulmonary Rehabilitation
  • Randomised Controlled Trial

Keywords

  • Pulmonary rehabilitation
  • chronic obstructive pulmonary disease (COPD)
  • Randomised controlled trial
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 40 to 75 years.
  • Confirmed medical diagnosis of (COPD) of moderate to severe severity, based on clinical evaluation and pulmonary function testing.
  • Clinically stable for at least 4 weeks following the last severe exacerbation, as confirmed by the treating pulmonologist.
  • Referred to an outpatient pulmonary rehabilitation program due to persistent symptoms and a history of exacerbations, with moderate to severe dyspnea (Medical Research Council [MRC] dyspnea scale score > 2), according to physician assessment.
  • Completed at least 6 out of 8 sessions of a standard 8-week initial pulmonary rehabilitation program.

Exclusion criteria

Exclusion Criteria:

  • Presence of medical to physical exercise, including unstable cardiovascular conditions (e.g., recent myocardial infarction, uncontrolled arrhythmias), severe musculoskeletal or neurological disorders, recent surgery, or acute medical conditions (e.g., recent stroke) that impair participation.
  • Severe cognitive impairment that limits the ability to understand instructions or participate actively in the program.
  • Unstable psychiatric disorders that may compromise adherence to or continuity with the exercise regimen.
  • Lack of availability or refusal to attend the scheduled sessions of the community-based exercise program.
  • Participation in another pulmonary rehabilitation program within the 6 months prior to study enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Supervised multidimensional pulmonary rehabilitation maintenance program

    Participants assigned to the intervention group will engage in a supervised, multidimensional pulmonary rehabilitation maintenance program over a period of three months. This program will consist of two weekly sessions of supervised exercise and a total of six educational sessions, each lasting approximately 20 minutes, delivered twice per month. The educational sessions will address key topics such as the prevention and management of chronic obstructive pulmonary disease (COPD) exacerbations and the adoption of healthy lifestyle behaviors. All sessions will be conducted at a comprehensive healthcare center by a physiotherapist who serves as both the program facilitator and case manager. The aim of this intervention is to sustain the clinical benefits achieved during the initial 8-week pulmonary rehabilitation program and to promote long-term self-management and functional capacity.

    Behavioral: Interdisciplinary intervention

  • No intervention
    Standard physical activity recommendations and unsupervised home exercise

    The control group will receive general recommendations for physical activity and a table of exercises to be performed at home, as established in standard clinical practice. They will not receive supervised interventions, however, they will be followed during the 12 months of the study and evaluated at the same times and with the same variables as the intervention group (baseline (T0), 3 months (T1), 6 months (T2), and 12 months (T3)).

Interventions

  • BehavioralInterdisciplinary intervention

    This intervention integrates a structured, interdisciplinary educational and physical activity approach specifically designed for individuals with COPD who have completed a standard pulmonary rehabilitation program. The program is distinguished by its incorporation of six monthly educational sessions addressing key lifestyle-related topics, including sleep hygiene, nutrition based on the Mediterranean diet, smoking cessation, alcohol reduction, and clinical self-management. In parallel, participants engage in twice-weekly exercise sessions tailored to their individual capacity, combining aerobic, strength, and functional training. Exercise intensity is prescribed based on initial functional assessments, at 50-80% of the average speed achieved in the six-minute walk test or the workload reached in an incremental cycle ergometer test. All sessions are supervised by physiotherapists and emphasize patient empowerment, behavioral change, and long-term disease management

06

What researchers measure

Primary outcomes

  1. Dyspnea (Dyspnea-12 total score)

    Dyspnea will be assessed using the Dyspnea-12 (D-12) questionnaire. The D-12 is a validated self-administered tool that quantifies breathlessness across 12 descriptors (physical and affective). Each item is scored from 0 (none) to 3 (severe), yielding a total score from 0 to 36, with higher scores indicating greater severity. The primary outcome will be the D-12 total score at Month 12, compared between intervention and control groups.

    Time frame: Month 12 post-baseline

Secondary outcomes

  1. Treatment Adherence (% attendance)

    Adherence will be measured as the percentage of attended supervised rehabilitation sessions out of the total prescribed. A threshold of ≥80% will define adequate adherence.

    Time frame: From Baseline to Month 12

  2. Disease-specific Health-related Quality of Life (COPD Assessment Test, CAT total score)

    The CAT is an 8-item validated questionnaire scored 0-40, with higher scores reflecting greater impact of COPD. A change ≥2 points is considered clinically significant.

    Time frame: Baseline, Month 3, Month 6, Month 12

  3. General Health-related Quality of Life (EQ-5D-5L index and VAS score)

    General health-related quality of life will be assessed with the EQ-5D-5L, which includes five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a visual analog scale (VAS) from 0 (worst health) to 100 (best health). Utility indices will be calculated to estimate quality-adjusted life years (QALYs) for economic evaluation.

    Time frame: Baseline, Month 3, Month 6, Month 12

  4. Exercise Capacity (6-minute walk test distance, meters)

    Exercise capacity will be measured by total distance walked in the 6-minute walk test, referenced to sex- and age-adjusted norms.

    Time frame: Baseline, Month 3, Month 6, Month 12

  5. Respiratory Function (FEV1, FVC, DLCO, % predicted)

    Pulmonary function will be evaluated by spirometry, with results expressed as % predicted based on international reference values.

    Time frame: Baseline, Month 12

  6. Direct Healthcare Costs

    Direct healthcare costs will be calculated from the healthcare provider perspective, based on hospitalizations, unscheduled visits, and medication use. Costs will be expressed in euros (€) for 2025. Unit of Measure: Euros (€)

    Time frame: From Baseline to Month 12

  7. Quality-adjusted Life Years (QALYs)

    QALYs will be estimated using EQ-5D-5L utility scores and area-under-the-curve methods. Unit of Measure: QALYs

    Time frame: From Baseline to Month 12

  8. Cost-utility Ratio

    Incremental cost-utility ratios (ICURs) will be calculated by dividing incremental costs (€) by incremental QALYs gained between intervention and control groups. Bootstrapping methods will be used to account for uncertainty. Unit of Measure: Incremental cost per QALY (€ / QALY)

    Time frame: From Baseline to Month 12

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Benjafield A, Tellez D, Barrett M, et al. An estimate of the European prevalence of COPD in 2050. Eur Respir J. 2021;58(suppl 65):OA2866. doi:10.1183/13993003.congress-2021.OA2866
  • Ekstrom MP, Bornefalk H, Skold CM, Janson C, Blomberg A, Bornefalk-Hermansson A, Igelstrom H, Sandberg J, Sundh J. Minimal Clinically Important Differences and Feasibility of Dyspnea-12 and the Multidimensional Dyspnea Profile in Cardiorespiratory Disease. J Pain Symptom Manage. 2020 Nov;60(5):968-975.e1. doi: 10.1016/j.jpainsymman.2020.05.028. Epub 2020 Jun 6. PubMed 32512047 ↗
  • Gabrio A, Mason AJ, Baio G. Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations. Pharmacoecon Open. 2017 Jun;1(2):79-97. doi: 10.1007/s41669-017-0015-6. PubMed 29442336 ↗
  • Ferro García R, García Ríos MC, Vives Montero MC. Un análisis de la adherencia al tratamiento en fisioterapia. Fisioterapia. 2004;26(6):333-339. doi:10.1016/S0211-5638(04)73120-X
  • Mantilla Toloza SC, Gómez-Conesa A. El Cuestionario Internacional de Actividad Física. Un instrumento adecuado en el seguimiento de la actividad física poblacional. Rev Iberoam Fisioter y Kinesiol. 2007;10(1):48-52. doi:10.1016/S1138-6045(07)73665-1
  • Oteo JA, Benavente P, Garzón M. Valores normativos de la fuerza de puño en la población española en edad laboral. Influencia de las variables antropométricas de la mano y el antebrazo. Rev Iberoam Cirugía la Mano. 2015;43(2):104-110. doi:10.1016/j.ricma.2015.09.005
  • Concha-Cisternas Y, Petermann-Rocha F, Castro-Pinero J, Parra S, Albala C, Wyngard VV, Vasquez J, Cigarroa I, Celis-Morales C. [Handgrip strength as a predictor of adverse health outcomes]. Rev Med Chil. 2022 Aug;150(8):1075-1086. doi: 10.4067/S0034-98872022000801075. Spanish. PubMed 37358156 ↗
  • ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. PubMed 12091180 ↗
  • Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7. doi: 10.1164/ajrccm.158.5.9710086. PubMed 9817683 ↗
  • Agusti A, Fernandez-Villar A, Capelastegui A, Garcia-Losa M, Velasco B, Sanchez G. Validity Study of Catalan, Galician and Basque Language Versions of the COPD Assessment Test and Equivalence With the Spanish Version. Arch Bronconeumol. 2017 Jun;53(6):311-317. doi: 10.1016/j.arbres.2016.10.003. Epub 2016 Dec 13. English, Spanish. PubMed 27986409 ↗
  • Hernandez G, Garin O, Pardo Y, Vilagut G, Pont A, Suarez M, Neira M, Rajmil L, Gorostiza I, Ramallo-Farina Y, Cabases J, Alonso J, Ferrer M. Validity of the EQ-5D-5L and reference norms for the Spanish population. Qual Life Res. 2018 Sep;27(9):2337-2348. doi: 10.1007/s11136-018-1877-5. Epub 2018 May 16. PubMed 29767329 ↗
  • Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):277-83. doi: 10.1016/s0163-8343(03)00043-4. PubMed 12850660 ↗
  • Amado Diago CA, Puente Maestu L, Abascal Bolado B, Aguero Calvo J, Hernando Hernando M, Puente Bats I, Aguero Balbin R. Translation and Validation of the Multidimensional Dyspnea-12 Questionnaire. Arch Bronconeumol (Engl Ed). 2018 Feb;54(2):74-78. doi: 10.1016/j.arbres.2017.08.001. Epub 2017 Nov 6. English, Spanish. PubMed 29122333 ↗
  • Agusti A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, Lopez Varela MV, Wedzicha JA, Vogelmeier CF. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP. No abstract available. PubMed 36856433 ↗
  • Gloeckl R, Marinov B, Pitta F. Practical recommendations for exercise training in patients with COPD. Eur Respir Rev. 2013 Jun 1;22(128):178-86. doi: 10.1183/09059180.00000513. PubMed 23728873 ↗
  • Carneiro-Barrera A, Amaro-Gahete FJ, Jurado-Fasoli L, Saez-Roca G, Martin-Carrasco C, Tinahones FJ, Ruiz JR. Effect of a Weight Loss and Lifestyle Intervention on Dietary Behavior in Men with Obstructive Sleep Apnea: The INTERAPNEA Trial. Nutrients. 2022 Jun 30;14(13):2731. doi: 10.3390/nu14132731. PubMed 35807913 ↗
  • Carneiro-Barrera A, Amaro-Gahete FJ, Saez-Roca G, Martin-Carrasco C, Palmeira AL, Ruiz JR. Interdisciplinary Weight Loss and Lifestyle Intervention for Daily Functioning and Psychiatric Symptoms in Obstructive Sleep Apnea: The INTERAPNEA Randomized Clinical Trial. J Clin Psychiatry. 2023 Jun 12;84(4):22m14502. doi: 10.4088/JCP.22m14502. PubMed 37339363 ↗
  • Carneiro-Barrera A, Amaro-Gahete FJ, Guillen-Riquelme A, Jurado-Fasoli L, Saez-Roca G, Martin-Carrasco C, Buela-Casal G, Ruiz JR. Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity: The INTERAPNEA Randomized Clinical Trial. JAMA Netw Open. 2022 Apr 1;5(4):e228212. doi: 10.1001/jamanetworkopen.2022.8212. PubMed 35452108 ↗
  • Ambrosino N, Bertella E. Lifestyle interventions in prevention and comprehensive management of COPD. Breathe (Sheff). 2018 Sep;14(3):186-194. doi: 10.1183/20734735.018618. PubMed 30186516 ↗
  • Holland AE, Cox NS, Houchen-Wolloff L, Rochester CL, Garvey C, ZuWallack R, Nici L, Limberg T, Lareau SC, Yawn BP, Galwicki M, Troosters T, Steiner M, Casaburi R, Clini E, Goldstein RS, Singh SJ. Defining Modern Pulmonary Rehabilitation. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2021 May;18(5):e12-e29. doi: 10.1513/AnnalsATS.202102-146ST. PubMed 33929307 ↗
  • Blackstock FC, Lareau SC, Nici L, ZuWallack R, Bourbeau J, Buckley M, Durning SJ, Effing TW, Egbert E, Goldstein RS, Kelly W, Lee A, Meek PM, Singh S; American Thoracic Society, Thoracic Society of Australia and New Zealand, Canadian Thoracic Society, and British Thoracic Society. Chronic Obstructive Pulmonary Disease Education in Pulmonary Rehabilitation. An Official American Thoracic Society/Thoracic Society of Australia and New Zealand/Canadian Thoracic Society/British Thoracic Society Workshop Report. Ann Am Thorac Soc. 2018 Jul;15(7):769-784. doi: 10.1513/AnnalsATS.201804-253WS. PubMed 29957038 ↗
  • Burns DK, Wilson EC, Browne P, Olive S, Clark A, Galey P, Dix E, Woodhouse H, Robinson S, Wilson A. The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Trial. Appl Health Econ Health Policy. 2016 Feb;14(1):105-15. doi: 10.1007/s40258-015-0199-9. PubMed 26346590 ↗
  • Cecins N, Geelhoed E, Jenkins SC. Reduction in hospitalisation following pulmonary rehabilitation in patients with COPD. Aust Health Rev. 2008 Aug;32(3):415-22. doi: 10.1071/ah080415. PubMed 18666869 ↗
  • McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Feb 23;2015(2):CD003793. doi: 10.1002/14651858.CD003793.pub3. PubMed 25705944 ↗
  • Spencer LM, McKeough ZJ. Maintaining the benefits following pulmonary rehabilitation: Achievable or not? Respirology. 2019 Sep;24(9):909-915. doi: 10.1111/resp.13518. Epub 2019 Mar 19. PubMed 30891887 ↗
  • Guell MR, Cejudo P, Ortega F, Puy MC, Rodriguez-Trigo G, Pijoan JI, Martinez-Indart L, Gorostiza A, Bdeir K, Celli B, Galdiz JB. Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. Am J Respir Crit Care Med. 2017 Mar 1;195(5):622-629. doi: 10.1164/rccm.201603-0602OC. PubMed 27611807 ↗
  • Jenkins AR, Gowler H, Curtis F, Holden NS, Bridle C, Jones AW. Efficacy of supervised maintenance exercise following pulmonary rehabilitation on health care use: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018 Jan 10;13:257-273. doi: 10.2147/COPD.S150650. eCollection 2018. PubMed 29391784 ↗
  • Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, Puhan MA, Hoogendoorn M, Garrod R, Schols AM, Carlin B, Benzo R, Meek P, Morgan M, Rutten-van Molken MP, Ries AL, Make B, Goldstein RS, Dowson CA, Brozek JL, Donner CF, Wouters EF; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. doi: 10.1164/rccm.201309-1634ST. PubMed 24127811 ↗
  • Beauchamp MK, Evans R, Janaudis-Ferreira T, Goldstein RS, Brooks D. Systematic review of supervised exercise programs after pulmonary rehabilitation in individuals with COPD. Chest. 2013 Oct;144(4):1124-1133. doi: 10.1378/chest.12-2421. PubMed 23429931 ↗
  • Alison JA, McKeough ZJ, Johnston K, McNamara RJ, Spencer LM, Jenkins SC, Hill CJ, McDonald VM, Frith P, Cafarella P, Brooke M, Cameron-Tucker HL, Candy S, Cecins N, Chan AS, Dale MT, Dowman LM, Granger C, Halloran S, Jung P, Lee AL, Leung R, Matulick T, Osadnik C, Roberts M, Walsh J, Wootton S, Holland AE; Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. Australian and New Zealand Pulmonary Rehabilitation Guidelines. Respirology. 2017 May;22(4):800-819. doi: 10.1111/resp.13025. Epub 2017 Mar 24. PubMed 28339144 ↗
  • Jenkins S, Hill K, Cecins NM. State of the art: how to set up a pulmonary rehabilitation program. Respirology. 2010 Nov;15(8):1157-73. doi: 10.1111/j.1440-1843.2010.01849.x. PubMed 20920127 ↗
  • Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravitlles M. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. Eur Respir J. 2019 Jul 18;54(1):1900610. doi: 10.1183/13993003.00610-2019. Print 2019 Jul. No abstract available. PubMed 31000678 ↗

Individual participant data

Plan to share: Yes — Individual participant data (IPD) underlying published results, including de-identified data on primary and secondary outcomes, will be made available upon reasonable request. Data will be shared after publication of the main results, for non-commercial academic use, and upon approval of a data-sharing agreement. Supporting documents such as the study protocol and statistical analysis plan will also be available.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is close to that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Feb 6, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2028was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Arnau de Vilanova University Hospital · Lleida, Spain
Show 1 removed
  • Arnau de Vilanova University Hospital · Lleida, Spain
Nov 4, 2026
Primary completion
Oct 2026→Oct 2027
Nov 4, 2026
Study completion
Oct 2026→Oct 2028
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • Arnau de Vilanova University Hospital · Lleida, Spain
    Show 1 removed
    • Arnau de Vilanova University Hospital · Lleida, Spain
    Primary completion Oct 2026→Oct 2027
    Study completion Oct 2026→Oct 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07394712
Lead sponsor
Institut de Recerca Biomèdica de Lleida
Responsible party
Jessica González Gutiérrez MD, PhD (Clinical Professor, Institut de Recerca Biomèdica de Lleida) — Principal investigator
First posted
Feb 6, 2026
Start date
Oct 1, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Jessica G MD, PhD, MD, PhD
Contact
jgonzalezgutierrez88@gmail.com
973702497
Ferran Barbé, MD, PhD
Contact
febarbe.lleida.ics@gencat.cat
973702959

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion